About: Evaluation of three immunochromatographic tests for rapid detection of antibodies against SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of three immunochromatographic tests for rapid detection of antibodies against SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of three immunochromatographic tests for rapid detection of antibodies against SARS-CoV-2
Creator	García-Rodríguez, Julio Alguacil-Guillén, Marina Bloise, Ivan González-Donapetry, Patricia González-García, Juan Mingorance, Jesus Tornero-Marin, Carolina Virginia Guedez-López, Gladys
Source	Medline; PMC
abstract	Lateral flow immunoassays (LFIA) for rapid detection of specific antibodies (IgM and IgG) against SARS-CoV-2 in different human specimens have been developed in response to the pandemic. The aim of this study is to evaluate three immunocromathographic assays (Sienna®, Wondfo® and Prometheus®) for detection of antibodies against SARS-CoV-2 in serum samples, considering RT-qPCR as a reference. A total of 145 serum samples from 145 patients with clinical suspicion of COVID-19 were collected: all of the samples were tested with Sienna®, 117 with Wondfo® and 89 with Prometheus®. The overall results of sensitivity, specificity, positive predictive value and negative predictive value obtained were as follows: 64.4%, 75%, 85.5% and 47.8% with Sienna®; 45.2%, 81.8%, 80.5% and 47.4% with Wondfo® and 75.5%, 12.5%, 51.4% and 29.4% with Prometheus®. The accuracy of the test for Sienna®, Wondfo® and Prometheus® was 67.6%, 59% and 47.2%, with a prevalence of COVID-19 of 69.7%, 62.4% and 55.1% respectively. Sensitivity of the three tests (Sienna®, Wondfo® and Prometheus® respectively) along the three different stages was 36.6%, 18.8% and 68.6% in the early stage (first week); 81.3%, 74.1% and 90.9% in the intermediate stage (second week) and 100%, 83.3% and 100% in the late stage (third week). The results demonstrate that even though Prometheus® presented a high sensitivity, the specificity was notably lower than the other two tests. Sienna® showed the greatest contrast between sensitivity and specificity, achieving the best accuracy, followed by Wondfo®. The sensitivity of the three ICT assays was higher in late stages of the disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10096-020-04010-7) contains supplementary material, which is available to authorized users.
has issue date	2020-08-17(xsd:dateTime)
bibo:doi	10.1007/s10096-020-04010-7
bibo:pmid	32808111
has license	no-cc
sha1sum (hex)	8c2fd68ba66ad0883409d5cf010531c9f7c85929
schema:url	https://doi.org/10.1007/s10096-020-04010-7
resource representing a document's title	Evaluation of three immunochromatographic tests for rapid detection of antibodies against SARS-CoV-2
has PubMed Central identifier	PMC7431115
has PubMed identifier	32808111
schema:publication	Eur J Clin Microbiol Infect Dis
resource representing a document's body	covid:8c2fd68ba66ad0883409d5cf010531c9f7c85929#body_text
is schema:about of	named entity 'Prometheus' named entity 'reference' named entity 'developed' named entity 'SARS-CoV-2' named entity 'collected' named entity 'pandemic' named entity 'Evaluation' named entity 'RT-QPCR' named entity '81.3' named entity 'EARLY STAGE' covid:arg/8c2fd68ba66ad0883409d5cf010531c9f7c85929 named entity 'late' named entity 'Sienna' named entity 'SARS-CoV-2' named entity 'Sienna' named entity 'specificity' named entity 'demonstrate' named entity 'specificity' named entity 'flow' named entity 'tests' named entity 'test' named entity 'week' named entity 'SARS-CoV-2' named entity 'immunochromatographic' named entity 'COVID' named entity 'serum samples' named entity 'Lateral flow' named entity 'SARS-CoV-2' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'immune status' named entity 'RT-qPCR' named entity 'advanced stages' named entity 'IgG' named entity 'general population' named entity 'pneumonia' named entity 'IgM' named entity 'Lateral flow' named entity '19, 20' named entity 'sensitivity, specificity' named entity 'complementary technique' named entity 'serum or plasma' named entity 'serological tests' named entity 'RdRp' named entity 'infection' named entity 'specific test' named entity 'serum samples' named entity 'immune response' named entity 'SARS-CoV-2' named entity 'nasopharyngeal swabs' named entity 'SARS-CoV-2' named entity 'false positives' named entity 'pathogens' named entity 'PPV' named entity 'Emergency Department' named entity 'COVID' named entity 'sensitivity and specificity' named entity 'SARS-CoV-2' named entity 'IgM' named entity 'Emergency Department' named entity 'IgG' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'RT-qPCR' named entity 'IgM' named entity 'false positives' named entity 'IgG' named entity 'healthcare workers' named entity 'acquired immunity' named entity 'serologic tests' named entity 'COVID-19 pandemic' named entity 'antibodies' named entity 'pneumonia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software